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Background. Interventions such as opiate substitution therapy (OST) and high-coverage needle and syringe
programs (HCNSP) cannot substantially reduce hepatitis C virus (HCV) prevalence among people who inject drugs
(PWID). HCV antiviral treatment may prevent onward transmission. We project the impact of combining OST,
HCNSP, and antiviral treatment on HCV prevalence/incidence among PWID.
Methods. An HCV transmission model among PWID was used to project the combinations of OST, HCNSP,
and antiviral treatment required to achieve different prevalence and incidence reductions within 10 years for 3
chronic prevalence scenarios and the impact of HCV treatment if only delivered through OST programs. Multivari-
ate and univariate sensitivity analyses were performed.
Results. Large reductions (>45%) in HCV chronic prevalence over 10 years require HCV antiviral treatment.
Scaling up OST and HCNSP substantially reduces the treatment rate required to achieve speciﬁc HCV prevalence re-
ductions. If OST and HCNSP coverage were increased to 40% each (no coverage at baseline), then annually treating
10, 23, or 42 per 1000 PWID over 10 years would halve prevalence for 20%, 40%, or 60% baseline chronic HCV
prevalences, respectively. Approximately 30% fewer treatments are necessary with new direct-acting antivirals. If
coverage of OST and HCNSP is 50% at baseline, similar prevalence reductions require higher treatment rates for the
same OST and HCNSP coverage.
Conclusions. Combining antiviral treatment with OST with HCNSP is critical for achieving substantial reduc-
tions (>50%) in HCV chronic prevalence over 10 years. Empirical studies are required on how best to scale up anti-
viral treatment and combine treatment with other interventions.
The global burden of liver disease caused by hepatitis C
virus (HCV) is increasing faster than other causes [1, 2].
In developed countries the majority of transmissions and
cases are among people who inject drugs (PWID) [1]. In
the UK, PWID acquire >90% of HCV infections [3].
HCV prevalence among PWID can vary 2–3 fold within
countries, with chronic prevalences of 20% in some areas
up to >60% in others [4].
High-coverage needle and syringe programs (HCNSP)
and opiate substitution therapy (OST) are key primary
interventions, and emerging evidence suggests they can
greatly reduce an individual’s HCV risk [5]. Modelling
has suggested that these interventions alone may not al-
ways lead to substantial reductions inHCVprevalence [6].
However, HCNSP and OST have other beneﬁts including
reducing HIV transmission [7], drug-related deaths [8],
and drug-related crime [9]. In addition, there may be
circumstances where their scale-up could be sufﬁcient
for achieving large reductions in HCV prevalence.
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We have shown HCV treatment could have a primary role in
prevention if delivered at sufﬁcient levels to PWID [10–14] and
can be more cost-effective than treating ex- or non-PWID
because of prevented secondary infections [15]. We consider
the impact of combining OST, HCNSP, and HCV treatment on
HCV prevalence and incidence among PWID.
METHODS
Model Description
We extended our dynamic, deterministic model of HCV trans-
mission and treatment among PWID [10] to include move-
ment of PWID through various intervention states (OST and
HCNSP, deﬁned as obtaining 1 or more sterile syringes from an
NSP for each injection). The model schematic and equations
can be found in the Supplementary material.
Brieﬂy, all PWID are initially susceptible (Xj,k, where sub-
scripts represent intervention coverage such that off/on HCNSP
[ j = 0 or 1, respectively] and off/on OST [k = 0 or 1, respective-
ly]) and become HCV infected at a per-capita rate, λj,k, speciﬁc
to that intervention state. A proportion (δ) of those acutely in-
fected will spontaneously clear infection and be at risk of rein-
fection (Ej,k), while the remainder (1− δ) proceed to chronic
infection, Cj,k. Chronically infected PWID can be put on antivi-
ral treatment (Tj,k) at a rate of Φ per 1000 PWID annually for a
duration 1/ω, whereupon a proportion (α) attain sustained
viral response (SVR) and move to the previously infected com-
partment, Ej,k, where they are at risk of reinfection. Those who
do not attain SVR (1− α) move to the treatment failure com-
partment, Fj,k, where we assume they cannot be retreated.
PWID leave all stages through permanent cessation of drug use
(μ1) or death due to drug- or nondrug-related causes (μ2). The
model does not include an acute infection category due to their
small probable contribution (<2%) to HCV transmission even
if they have heightened viremia [14] and also ignores any im-
munity following treatment or spontaneous clearance. Immu-
nity is neglected in part because the evidence is uncertain [16]
but also because previous analyses suggested that incorporation
of partial immunity has negligible impact [6, 10].
PWID are tracked through 4 intervention states: no interven-
tion, OST only, HCNSP only, and OST with HCNSP. All
PWID initially enter the no-intervention state. We assume the
per-capita recruitment rates to OST (β) and HCNSP (η) are in-
dependent of the current intervention state [6]. The rates of
leaving OST and HCNSP are γ and κ, respectively.
The forces of infection for each susceptible state were deﬁned
by the relative risk in that state, such that infectivity and sus-
ceptibility were altered by a factor Γ, Π, or Β if the PWID was
on OST, HCNSP, or both, respectively. The chance of a PWID
having a transmission event with any PWID from another risk
state and infectious status was assumed to be proportional to the
relative frequency of transmission events for PWID in that state.
Due to rapid reductions in viral load while on antiviral treat-
ment, we assume the transmission potential of those on treat-
ment is scaled down by a factor depending on the SVR rate.
Intervention Parameters
Model parameters can be found in Table 1. Effect estimates for
PWID on OST or HCNSP were taken from a pooled analysis
of UK data [5, 6]. We use a pooled SVR rate for pegylated
interferon (pegIFN) and ribavirin (RBV) from a meta-analysis of
individuals who report actively injecting (median 61.4%, range
51.2%–71.6%) [17] and explore the impact of new IFN-free
direct-acting antiviral (DAA) treatments, using SVR rates from
phase II studies (median 90%, range 80%–100%) [18–20].
Modeled Scenario Analysis
We project the 10-year impact on HCV prevalence and incidence
for various combinations of scale-up of antiviral treatment
(from none at baseline), OST and HCNSP (from 0%, 20%, or
50% coverage of each at baseline) for 3 baseline HCV chronic
prevalence settings (20%, 40%, and 60%). We explore the impact
of treatment using peg-IFN + RBV or new IFN-free DAAs in
combination with scale-up of OST and HCNSP to a maximum
of 80% for each. To do this, we performed a multivariate uncer-
tainty analysis by running the model with 1000 randomly
sampled parameter values from the uncertainty distributions for
the antiviral treatment SVR and the efﬁcacy of OST and HCNSP
on reducing HCV transmission risk (Table 1). We utilize the
projections to determine combinations of antiviral treatment,
OST and HCNSP scale-up that halve baseline chronic prevalence
within 10 years. Contour maps show what prevalence and inci-
dence reductions are achievable with various levels of scale-up of
antiviral treatment, OST and HCNSP using median estimates for
the efﬁcacy of OST, HCNSP, and SVR.
HCV Treatment Delivered Within OST Programs
Since HCV antiviral treatment may best be delivered to PWID
alongside OST, we explore the impact of restricting treatment to
only those on OST. We calculate the minimum coverage of OST
and HCNSP required to achieve different relative prevalence re-
ductions for 20%, 40%, and 60% HCV chronic prevalence sce-
narios with no interventions at baseline. Model projections
assume median estimates for efﬁcacy of OST, HCNSP, and SVR
for peg-IFN + RBV and assume either all chronically infected
PWID on OST are treated annually (limited by the HCV preva-
lence) or 5% of PWID on OST are treated annually.
Sensitivity Analysis
We perform a 1-way sensitivity analysis on the intervention
combinations required to halve baseline chronic prevalence
over 10 years for the 40% baseline prevalence scenario with no
baseline OST or HCNSP. Model projections assume median
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estimates for efﬁcacy of OST, HCNSP, and SVR for peg-IFN +
RBV (Table 1) and explore the impact of including PWID risk
heterogeneity and varying the exit rate (due to injecting cessa-
tion or death). For the risk heterogeneity sensitivity analysis, we
simulate a high-risk population comprised of 50% of PWID
(the remainder low risk), no turnover between high- and low-
risk states, and increased HCV risk among the high-risk group
of 2- or 6-fold that of the low-risk PWID. We also explore sce-
narios where the high- and low-risk groups mix proportionally
or partially (50%) assortatively and the effect of assuming that a
proportion (20%) of PWID never go on OST.
RESULTS
Scaling Up From Baseline With peg-IFN + RBV
For a baseline chronic HCV prevalence of 20%, 40%, or 60%,
Figure 1A shows that by combining interventions (involving
peg-IFN + RBV), chronic prevalence can halve within 10 years.
The model projections vary considerably (95% credible interval
[CrI] deviates 6%–21% from median projections for treatment
only, with increasing uncertainty including OST and HCNSP
scale-up [24%–71% deviation with 60% scale-up of OST and
HCNSP]). Scaling up OST and HCNSP will substantially de-
crease the treatment rate required to halve prevalence within 10
years (by 19%–27% or 39%–44%, respectively). Hence, if cover-
age of OST and HCNSP were both increased to 40%, then an-
nually treating 10 (95% CrI, 8–14), 23 (95% CrI, 19–32), and
42 (95% CrI, 35–58) per 1000 PWID would halve prevalence
over 10 years in the 20%, 40%, or 60% chronic HCV prevalence
scenarios, respectively, as compared to treating 18 (95% CrI,
17–20), 38 (95% CrI, 36–42), and 68 (95% CrI, 64–83) per
1000 PWID annually with no OST or HCNSP coverage.
Contour maps of the relative prevalence reductions for
various combinations of intervention scale-up over 10 years
show that scale-up of OST and HCNSP reduces the required
treatment rate necessary to achieve a given impact (Figure 2)
and that HCV treatment is required to achieve >45% reduction
in prevalence within 10 years.
Table 1. Model Parameters and Sources
Parameter Symbol Value(s) or Range Units References
HCV chronic prevalencea Vary π to fit 20%, 40%, or 60% . . . . . .
PWID population size Vary θ to fit 1000 . . . . . .
Exit rate (cessation + death) μ1 + μ2 8.5% per year As in [6, 10], sensitivity
analysis varied 5%–20%
per year [21, 26–28]
Recruitment rate on OST β (0%–55%) per month Varied to achieve a range of
intervention coverages
Recruitment rate on HCNSP η Set equal to recruitment
rate on OST
per month Varied to achieve a range of
intervention coverages
Duration on OST 12/γ 8 months [6, 8]
Duration on HCNSP 12/κ 8 months [6] Few data, assumed the
same as OST
Proportion spontaneously clear δ 25% . . . [29]
Annual PWID treatment rate Φ 0–100 per 1000 PWID Varied to achieve a range of
intervention coverages
PEG-IFN + RBV SVR α 61.4% (51.2%–71.6%) . . . [17]Sampled from a
uniform distribution
IFN-free DAA SVR α 90% (80%–100%) . . . [18–20]Sampled from a
uniform distribution
PEG-IFN + RBV duration 52/ω 24 weeks [30]
IFN-free DAA duration 52/ω 12 (8–16) weeks [18–20] Sampled from a
uniform distribution
Relative risk for acquiring HCV on OST Γ 0.48 (0.17–1.33) . . . [5, 6] Sampled from a
lognormal distribution
Relative risk for acquiring HCV on HCNSP Π 0.50 (0.22–1.12) . . . [5, 6] Sampled from a
lognormal distribution
Relative risk for acquiring HCV on OST
and HCNSP
Γ 0.21 (0.08–0.52) . . . [5, 6] Sampled from a
lognormal distribution.
Abbreviations: DAAs, direct-acting antivirals; HCNSP, high-coverage needle and syringe programs, defined as receiving 1 or more sterile syringes from an NSP per
injection per month; OST, opiate substation therapy; peg-IFN, pegylated interferon; PWID, people who inject drugs; RBV, ribavirin; SVR, sustained viral response.
a Used to estimate the infection rate, π (vary π and fit to the hepatitis C virus chronic prevalence).
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For a given coverage of OST and HCNSP, greater relative re-
ductions in incidence are achieved at 10 years than for preva-
lence, with the relative impact on incidence being 101%–130%
greater than the impact on prevalence for OST and HCNSP
scale-up to 60% coverage (Supplementary Figure 2). In con-
trast, treatment alone has equal impact on incidence as preva-
lence.
Scaling Up From Baseline With IFN-free DAAs
Results simulating the likely impact of new IFN-free DAAs are
shown in Figures 1B and 2D–F and suggest that approximately
30% fewer treatments are necessary than with peg-IFN + RBV
to halve prevalence within 10 years. Increasing OST and
HCNSP coverage to 40% may only require annual treatment
rates of 7 (95% CrI, 6–10), 16 (95% CrI, 14–21), and 29 (95%
CrI, 25–39) per 1000 PWID for 20%, 40%, or 60% baseline
chronic prevalences, respectively, to achieve a halving of preva-
lence in 10 years.
Scaling Up From 20% or 50% Baseline Coverage of OST and
HCNSP With peg-IFN + RBV
Figure 1C shows the required levels of intervention scale-up nec-
essary for halving chronic prevalence within 10 years with 50%
OST and HCNSP at baseline. For example, prevalence can be
halved within 10 years by increasing OST and HCNSP coverage
from 50% to 70% and annually treating 12 (95% CrI, 11–14), 27
(95% CrI, 24–34), and 48 (95% CrI, 42–59) per 1000 PWID for
the 20%, 40%, or 60% chronic prevalence scenarios, respectively.
Scaling up OST and HCNSP from already moderate or high
coverage levels also leads to greater reductions in the number of
antiviral HCV treatments required to achieve chronic HCV
prevalence reductions as compared to scale-up from no OST
or HCNSP at baseline. At 20% coverage of OST and HCNSP at
baseline, achieving >40% prevalence reduction within 10 years
always requires scale-up of antiviral treatment, whereas at 50%
baseline coverage, treatment is always required to achieve >30%
prevalence reductions at 10 years (Supplementary Figure 3).
Scaling Up HCV Treatment Through OST Programs
Figure 3 shows the minimum coverage of OST and HCNSP
required (no coverage at baseline) to achieve different relative
reductions in prevalence at 10 years, while assuming either
there are no limits to treatment capacity/uptake within OST (all
infected PWID on OST are treated each year) or that 5% of
PWID on OST are treated annually. If all infected PWID on
OST can be treated annually, halving prevalence in 10 years re-
quires 18%–24% coverage of OST and HCNSP, whereas higher
coverage levels are required if only 5% of PWID on OST are an-
nually treated (25%–58% OST and HCNSP).
Figure 1. Combinations of annual treatment rates per 1000 injectors
and coverage of opiate substitution therapy (OST) and high-coverage
needle and syringe programs (HCNSP) required to reduce prevalence by
50% within 10 years. Results shown for 3 baseline chronic prevalence set-
tings (20%, 40%, and 60%). A and B, Assumes no intervention coverage
at baseline with OST and HCNSP scale-up to 0%, 20%, 40%, or 60% of
each and using pegylated interferon and ribavirin (peg-IFN + RBV) (A) and
interferon (IFN)-free direct-acting antivirals (DAAs) (B). C, Assumes 50%
coverage of OST and HCNSP at baseline with OST and HCNSP scale-up to
50%, 60%, 70%, or 80% of each using peg-IFN + RBV. The box-plots
signify the uncertainty (middle line is the median, limits of the boxes are
25% and 75% percentiles and whiskers are 2.5% and 97.5% percentiles)
in the impact projections due to uncertainty in the intervention effect
estimates.
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Sensitivity Analysis
At higher exit rates (ie, in populations with shorter durations of
injecting) scaling up OST and HCNSP achieves more impact
than at lower exit rates, whereas the opposite occurs for scaling
up antiviral treatment, but less so (Supplementary Figure 4A
and B). Therefore, to halve prevalence within 10 years, a strat-
egy using treatment alone would require more treatments at a
high exit rate (shorter injecting duration) than at a low exit rate
(longer duration), but a strategy using just OST and HCNSP
would require the opposite (Supplementary Figure 4A). To
minimize the uncertainty around injecting duration, it is possi-
ble to choose an intervention combination that achieves the
same impact regardless of exit rate (Supplementary Figure 4C).
The model projections are insensitive to the inclusion of a
high-risk group, even if it comprised 50% of the population
with no turnover between high and low risk (Supplementary
Figure 4D). Only if the high-risk group has a 6-fold relative risk
and mixes partially assortatively with no turnover does the re-
quired number of treatments increase by a noticeable degree
(20%–35% for a given OST and HCNSP coverage). In contrast,
if there is turnover between risk groups, then heterogeneity has
little effect. Additionally, there is no difference in the required
treatment rates if 20% of the population never go on OST.
DISCUSSION
We projected the impact of combining OST, HCNSP, and HCV
antiviral treatment on HCV prevalence and incidence among
PWID. Halving chronic HCV prevalence within 10 years is not
possible using OST and HCNSP alone but is achievable in all
prevalence settings when combined with current treatments
(peg-IFN + RBV) and will be more achievable with new IFN-
free DAAs. For a given coverage of OST and HCNSP, greater
reductions in incidence are achieved at 10 years than for preva-
lence, whereas no difference is found with antiviral treatment.
This is because OST and NSP directly reduces incidence, while
treatment directly reduces prevalence by curing infections. In
general, increasing coverage of OST and HCNSP by 20% from
any level reduces the required number of treatments by about
30%. In settings with shorter average injecting durations (such as
South East Asia), scale-up of OST and HCNSP may be prefera-
ble as there is little time for the beneﬁts of antiviral treatment
to accrue. Conversely, in areas with long injecting durations
(such as Zurich [21]), OST and HCNSP impact will be much
reduced, so treatment is critical for achieving substantial HCV
reductions. Finally, heterogeneity in injecting risk has marginal
impact in most realistic scenarios.
Figure 2. Contour maps of the relative reductions in prevalence (%) at 10 years with combinations of antiviral treatment (y-axis) and opiate substitution
therapy/high-coverage needle and syringe program (OST and HCNSP) (x-axis) scale-up with no baseline coverage of OST, HCNSP, or treatment. Results
shown for 3 baseline hepatitis C virus chronic prevalence settings (20%, 40%, and 60%) with pegylated interferon and ribavirin (pegIFN + RBV) (A–C) and
IFN-free direct-acting antivirals (D–F). Projections used the median estimates for efﬁcacy of OST, HCNSP, and peg-IFN + RBV from Table 1.
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Limitations
These projections are based on a theoretical model with several
limitations. First, there is uncertainty in the model parameters
including efﬁcacy estimats for OST and HCV, and HCV antivi-
ral treatment SVR rates among PWID. Second, it remains to be
demonstrated that the higher treatment rates projected in some
of the scenarios can be achieved, although the new IFN-free
DAA treatment should make scale-up easier to implement, if
earlier trials suggesting shorter treatment duration, higher SVR
and lower toxicity than current treatment regimes [20] prove to
be true. Multivariate sensitivity analyses were used to explore
the implications of parameter uncertainty, including wide sam-
pling ranges around the SVR estimates to account for settings
with different SVR rates or genotype distributions.
In addition, complexities involved in scaling up each inter-
vention were not considered here. Previous modeling analyses
considered these issues for OST and HCNSP [6], but additional
case-ﬁnding interventions may be required.
Third, we neglect the other beneﬁts of OST and HCNSP,
such as the impact on reducing HIV transmission [7], drug-
related deaths [8], and drug-related crime [9]. These beneﬁts
would accrue in addition to any HCV beneﬁts and so give
added impetus to scaling up HCNSP and especially OST.
Implications
Overall, our work supports current recommendations on HCV
prevention issued by the European Centre for Disease Prevention
and Control that interventions be combined to achieve
maximum impact [22], as well as previous modeling studies that
have shown that scale-up of antiviral treatment [10–14, 23],
OST and HCNSP [6] among PWID can reduce prevalence in a
variety of chronic prevalence settings. However, the relative af-
fordability of each strategy is a key question, particularly with the
new DAAs. Current treatment with peg-IFN + RBV costs
between $16 000 and $33 000 per full treatment course, whereas
triple therapy with boceprevir and telaprevir costs approximately
$30 000–$80 000 [24]. By contrast, annual costs of delivering
OST have been estimated at $10–$15 per day ($3650–$5475 per
year) and high-coverage NSP may cost ∼$500 per year [25].
Therefore, strategies that increase OST and HCNSP in order to
minimize the number of antiviral HCV treatments required to
prevent and reduce chronic HCV are likely to be an efﬁcient use
of resources. Future work should address the optimal combina-
tion prevention intervention strategy that addresses both cost ef-
fectiveness and affordability.
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